Embed Size (px)
Citation preview
DHS Årsmøde og Generalforsamling d.18-‐19 Marts 2016.
På Hindsgavl Slot
Fredag d.18. Marts 12.00-‐13.00 Frokost 13.00-‐13.15 Velkomst ved Formanden
Fagligt Program:
”The changing landscape in multiple myeloma (MM)-‐ including health economical aspects”
Chairman: Professor, Overlæge, Dr.med. Niels Abildgaard. 13.15-‐14.15 ” Health economical aspects in treatment of MM or Access to cancer
drugs in UK”. David Bowen 14.15-‐15.15 ”Moab therapy in myeloma: preclinical rationale, clinical results and
strategies for improvement”. Henk Lokhorst 15.15-‐16.00 Kaffepause og Udstilling (Coffebreak) 16.00-‐17.00 ” State of the art" in treatment of multiple myeloma -‐ treatment
algorhytms in the new era.” Niels Abildgaard Generalforsamling 17.00-‐18.00 Middag 19.00-‐
Lørdag d.19. Marts Abstract session 1 Chairman: Carsten Niemann 9.00-‐ 9.10 Myc protein expression in multiple myeloma: clinicopathological
features and prognostic impact, Hanne E. H. Møller
9.10-‐ 9.20 FDG PET/CT and osteolytic bone disease in multiple myeloma, Julie Raeder Mortensen
9.20-‐ 9.30 Diffuse Large B-‐cell Lymphoma in the Rituximab Era: Real life analysis of patients with relapse or refractory disease. B. Arboe
9.30-‐ 9.40 15-‐year follow-‐up of the Nordic MCL2-‐trial: Still among the best -‐ but
still no cure, Christian W. Eskelund 9.40-‐ 9.50 Cereblon og dens rolle i behandlingsrespons og udvikling af resistens til
immunmodulerende stoffer. Kostas Dimopoulos
9.50-‐ 10.00 The JAK2 V617F mutation is a potential target for cancer immune therapy in the Philadelphia chromosome negative chronic myeloproliferative neoplasia, Morten Orebo Holmström
10.00-‐10.10 Methylation of cell-‐free circulating DNA in plasma predicts poor
outcome in diffuse large B-‐cell lymphoma, Lasse Sommer Kristensen 10.10-‐ 10.20 TP53 hotspot mutations are predictive of survival in primary central
nervous system lymphoma patients treated with combination chemotherapy, Helga D. Munch-‐Petersen
10.20 – 11.00 Pause og Udstilling
Abstract session 2 Chairman: Daniel el Fassi 11.00-‐ 11.10 Outcomes with Identical Treatment of Adults and Children (1-‐45 years)
with Philadelphia Chromosome-‐negative Acute Lymphoblastic Leukemia – Results of NOPHO ALL2008 in DK, Nina Toft
11.10-‐ 11.20 Hypogammaglobinemia predicts for shorter overall survival and shorter treatment free survival in CLL but does not impact the risk of infections – implications for development of individually tailored treatment in CLL, Michael Asger Andersen
11.20-‐ 11.30 Ultra deep targeted Next Generation Sequencing for the detection of subclonal TP53 aberrations in CLL, C Brieghel
11.30-‐ 11.40 Survival of DLBCL patients in first remission relative to a matched
background population, Lasse Hjort Jakobsen 11.40-‐ 11.50 Frequent mutations in epigenetic regulators in cytopenia of unknown
significance: Association with risk of progression to myelodysplastic syndrome,Hansen JW
11.50-‐ 12.00 Peripheral blood leukocyte telomere length and risk of infectious
disease: A prospective study of 75,919 individuals from the general population, Jens Helby
12.00-‐12.10 Consequences of new haemoglobin reference intervals in the general
population, Judith Ryberg-‐Nørholt 12.00-‐12.20 Årets Case, Rasmus Sørrig
12.30 Afslutning Sandwich
